Company Encyclopedia
View More
name
Inotiv
NOTV.US
Inotiv, Inc. provides nonclinical and analytical drug discovery and development services to the pharmaceutical and medical device industries in the United States, the Netherlands, and internationally. The company operates through two segments, Discovery and Safety Assessment (DSA) and Research Models and Services (RMS). The DMS segment manufactures scientific instruments for life sciences research and the related software for use by pharmaceutical companies, universities, government research centers, and medical research institutions under the company’s BASi product line.
757.90 B
NOTV.USMarket value -Rank by Market Cap -/-

Financial Score

15/12/2025 Update
D
Life Sciences Tools and ServicesIndustry
Industry Ranking57/61
Industry medianC
Industry averageC
Score Analysis
Peer Comparison
  • Criteria
    Rating
  • Profit ScoreE
    • ROE-44.78%E
    • Profit Margin-13.38%D
    • Gross Margin23.58%C
  • Growth ScoreC
    • Revenue YoY4.54%C
    • Net Profit YoY36.72%B
    • Total Assets YoY-1.31%D
    • Net Assets YoY-20.22%E
  • Cash ScoreD
    • Cash Flow Margin-747.58%E
    • OCF YoY4.54%C
  • Operating ScoreB
    • Turnover0.66B
  • Debt ScoreE
    • Gearing Ratio82.36%E

Valuation analysis

portai
P/E
1Y
3Y
5Y
10Y
P/E
-
Industry Ranking
-/-
  • P/E
  • Price
  • High
  • Median
  • Low
P/B
1Y
3Y
5Y
10Y
P/B
-
Industry Ranking
-/-
  • P/B
  • Price
  • High
  • Median
  • Low
P/S
1Y
3Y
5Y
10Y
P/S
-
Industry Ranking
-/-
  • P/S
  • Price
  • High
  • Median
  • Low
Dividend Yield
1Y
3Y
5Y
10Y
Dividend Yield
-
Industry Ranking
-/-
  • Dividend Yield
  • Price
  • High
  • Median
  • Low

Institutional View & Shareholder

Analyst Ratings

Rating
Percentage
    • Price
      --
    • Highest
      --
    • Lowest
      --
    News
    View More

    Inotiv Partners with VUGENE to Boost AI-Driven Drug Discovery

    Inotiv Inc. partners with VUGENE to integrate cloud-based bioinformatics into its Discovery & Translational Sciences Division, aiming to boost AI-driven drug discovery. The collaboration will enhance analysis of complex biological data and improve prediction of drug efficacy and safety, aiding faster decision-making in early-stage research.

    Reuters·
    US
    NOTV
    -4.91%
    Reuters·
    US
    NOTV
    -4.91%

    Inotiv Inc. Showcases CRO Growth Strategy and Operational Optimization in Investor Presentation

    Inotiv Inc., a contract research organization, presented its growth strategy and operational optimization in an investor presentation. The company focuses on a vertically integrated business model, optimizing sites for cost savings, and enhancing client experiences. It has strengthened compliance, modernized data management, and unified procedures across U.S. operations. Commercial strategies include expanding sales teams and promoting multi-site capabilities. Inotiv aims for growth through organic investments and mergers and acquisitions.

    Reuters·
    US
    NOTV
    -4.91%
    Reuters·
    US
    NOTV
    -4.91%

    Inotiv, Inc. Faces Business Risks Amid FDA Disruptions and Government Funding Challenges

    Inotiv, Inc. faces business risks due to FDA disruptions and government funding challenges, potentially delaying product approvals and impacting operations. Past government shutdowns and the COVID-19 pandemic have shown the potential for significant delays, threatening business continuity. The average NOTV stock price target is $3.00, indicating a 271.43% upside potential.

    Tip Ranks·
    US
    NOTV
    -4.91%
    Tip Ranks·
    US
    NOTV
    -4.91%

    Inotiv, Inc. Earnings Call: Growth Amid Challenges

    Inotiv, Inc.'s Q4 earnings call highlighted growth in the Discovery & Safety Assessment segment, with a 15.7% revenue increase and 61% rise in awards. The company achieved cost savings through RMS site consolidation, generating $14.3 million in cash from operations. Despite challenges like a cybersecurity incident and high interest expenses, Inotiv improved its financial position, reducing operating loss to $30.9 million. Forward guidance projects a 5.9% revenue increase, focusing on DSA margins and RMS consolidations for future savings.

    Tip Ranks·
    US
    NOTV
    -4.91%
    Tip Ranks·
    US
    NOTV
    -4.91%

    Inotiv | 10-K: FY2025 Revenue Beats Estimate at USD 513.02 M

    LB filings·
    US
    NOTV
    -4.91%
    LB filings·
    US
    NOTV
    -4.91%
    © 2025 Longbridge｜Disclaimer